Opioid Prescription Trends by Otolaryngologists for Medicare Part D Patients
- 1Northwestern University Feinberg School of Medicine Chicago Illinois USA
- 2Department of Otolaryngology‐Head and Neck Surgery Northwestern University Feinberg School of Medicine Chicago Illinois USA
Abstract
Objective: To characterize longitudinal trends in opioid prescription patterns among otolaryngologists in the Medicare Part D population spanning the COVID‐19 pandemic, including overall prescribing volume, drug‐type composition, and geographic variation.
Methods: The Centers for Medicare & Medicaid Services Part D Prescribers database was queried from 2013 to 2024 for opioid prescriptions by otolaryngologists. Outcomes included annual prescription counts, patient counts, total days supplied, and total cost. Data were normalized to per million Medicare part D beneficiaries and opioid prescription costs were inflation adjusted to 2024. Geographic variation was evaluated at the state and regional levels.
Results: Between 2013 and 2024, ENT opioid prescriptions declined 37.7% (4261 to 2655 per million beneficiaries), total days supplied decreased by 44.7%, and inflation‐adjusted cost decreased 53.5%. Prescriptions reached a nadir in 2020, followed by a partial rebound through 2024. Hydrocodone remained the most prescribed opioid throughout but declined substantially in both volume (−57.1%) and market share (77.6% to 53.4%), while oxycodone nearly doubled in volume (+92.2%), rising from 10.9% to 33.5% of all ENT opioid prescriptions. Tramadol increased by 70.0%. The Southern region had the most opioid prescriptions (800,507 claims per million beneficiaries), while the Northeast had the least (136,997). This represented a nearly six‐fold regional difference.
Conclusion: While overall ENT opioid prescribing has declined significantly over the past decade, a concurrent shift toward oxycodone represents an unintended consequence of hydrocodone rescheduling that warrants continued surveillance. Persistent geographic disparities suggest that prescriber stewardship efforts remain uneven across regions.
Related
- Trends in Opioid Use Among Medicare Beneficiaries by Race and Ethnicity
- Trends in Opioid Prescribing for Nonspecific Low Back Pain After CDC Guidelines and California Prescription Drug Monitoring Programs, 2012-2024
- Multi‐Center Evaluation of Opioid Administration or Prescription in Pediatric Oncology Patients Using the OMOP CDM
- Trends in detection of dementia among beneficiaries in Medicare advantage and traditional Medicare.
- Trends in the utilization of minimally invasive therapies for overactive bladder among older adults: a national Medicare study
BibTeX
@article{wang2026opioid,
title = {{Opioid Prescription Trends by Otolaryngologists for Medicare Part D Patients}},
author = {Larry W. Wang and Jack Peterson and Jason Zhang and Nikhil Sriram and Stephanie S. Smith and James C. Wang},
journal = {Laryngoscope investigative otolaryngology},
year = {2026},
month = oct,
doi = {10.1002/lio2.70568},
url = {https://europepmc.org/article/PMC/PMC13719288},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Opioid Prescription Trends by Otolaryngologists for Medicare Part D Patients
AU - Larry W. Wang
AU - Jack Peterson
AU - Jason Zhang
AU - Nikhil Sriram
AU - Stephanie S. Smith
AU - James C. Wang
PY - 2026
DA - 2026/10/29
JO - Laryngoscope investigative otolaryngology
DO - 10.1002/lio2.70568
UR - https://europepmc.org/article/PMC/PMC13719288
AB - Objective: To characterize longitudinal trends in opioid prescription patterns among otolaryngologists in the Medicare Part D population spanning the COVID‐19 pandemic, including overall prescribing volume, drug‐type composition, and geographic variation. Methods: The Centers for Medicare & Medicaid Services Part D Prescribers database was queried from 2013 to 2024 for opioid prescriptions by otolaryngologists. Outcomes included annual prescription counts, patient counts, total days supplied, and total cost. Data were normalized to per million Medicare part D beneficiaries and opioid prescription costs were inflation adjusted to 2024. Geographic variation was evaluated at the state and regional levels. Results: Between 2013 and 2024, ENT opioid prescriptions declined 37.7% (4261 to 2655 per million beneficiaries), total days supplied decreased by 44.7%, and inflation‐adjusted cost decreased 53.5%. Prescriptions reached a nadir in 2020, followed by a partial rebound through 2024. Hydrocodone remained the most prescribed opioid throughout but declined substantially in both volume (−57.1%) and market share (77.6% to 53.4%), while oxycodone nearly doubled in volume (+92.2%), rising from 10.9% to 33.5% of all ENT opioid prescriptions. Tramadol increased by 70.0%. The Southern region had the most opioid prescriptions (800,507 claims per million beneficiaries), while the Northeast had the least (136,997). This represented a nearly six‐fold regional difference. Conclusion: While overall ENT opioid prescribing has declined significantly over the past decade, a concurrent shift toward oxycodone represents an unintended consequence of hydrocodone rescheduling that warrants continued surveillance. Persistent geographic disparities suggest that prescriber stewardship efforts remain uneven across regions.
SN - 2378-8038
ER -